Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:

Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03836157
• Other study ID #: OUSCC-IMGN-001
• Status: Withdrawn
• Phase: Phase 2
• Start date: May 31, 2019
• Est. completion date: May 2022

Study information

• Verified date: June 2019
• Source: University of Oklahoma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1 (FRα)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and bevacizumab and see what effects (good and bad) that this combination treatment has on subjects with recurrent endometrial cancer.

Description:

SCREENING: During the screening portion of the study, the subject will need to have tumor tissue tested and other exams to determine if s/he may proceed to the treatment part of the study. The subject's tumor tissue will be tested from either a previous or recent surgery or biopsy to see if it contains the FRα protein. If the tumor is positive and the patient meets all other eligibility, then the subject may proceed to treatment.

TREATMENT: Study drugs (IMGN853 and bevacizumab) will be given by vein (IV) once each cycle on day 1 of 21 day cycle.

Regular cancer care exams, tests, and procedures will occur. Additionally, an eye doctor visit with complete eye examination every other treatment cycle. Subjects will also self-administer eye drops as prescribed by the eye doctor.

Study participation is up to three years.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2022
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with histological diagnosis of endometrial carcinoma (including others per protocol).

2. Expression of folate receptor alpha (FRa) on either archival tumor or new biopsy is required.

3. Measurable disease

4. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy or established treatments.

5. At least 1 prior platinum-based chemotherapeutic regimen, but not more than 2 prior chemotherapeutic regimens, for management of endometrial carcinoma. Prior treatment may include chemotherapy, or chemotherapy/radiation therapy . Chemotherapy administered in conjunction with primary radiation as a radio-sensitized therapy will be considered a systemic chemotherapy regimen

6. Female patients 18 years or older

7. Eastern Cooperative Oncology Group performance status of 0 to 1;

8. Patient must have archival tumor tissue available from the primary or recurrent cancer prior to first dose. If archival tumor sample is not available, tumor sample from new biopsy is acceptable.

9. Patients must have acceptable organ and marrow function as defined per protocol

10. Time from prior therapy:

1. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy.

2. Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment

11. Patients must have a life expectancy of at least 3 months

12. Patients should have no major existing co-morbidities or medical conditions that will preclude therapy

13. Ability to understand and the willingness to sign a written informed consent document, and to comply with the requirements of the protocol; with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

14. Female patients of reproductive potential and their male partners must agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through at least twelve weeks after the last dose of IMGN853 and/ or bevacizumab.

Exclusion Criteria:

1. Previous treatment with mirvetuximab.

2. Invasive cancer within the past 2 years. Noninvasive non-melanoma skin cancers are not exclusions if they have undergone complete resection.

3. Untreated or symptomatic central nervous system (CNS) metastases. Patients with asymptomatic CNS metastases are eligible provided they have been clinically stable for at least 4 weeks prior to first dose of study treatment), have no evidence of new or emerging CNS metastasis, and are not using steroids for at least 7 days prior to first dose of study treatment.

4. Unstable angina or myocardial infarction within the previous 6 months; uncontrolled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications); prior history of hypertensive crisis or hypertensive encephalopathy; symptomatic congestive heart failure (NYHA Class III and IV); uncontrolled cardiac arrhythmia; clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm), severe aortic stenosis; clinically significant peripheral vascular disease; history of any CNS cerebrovascular ischemia or stroke within the last 6 months.

5. Active pulmonary disease or other coexisting medical condition that would preclude full compliance with the study.

6. Receiving any other investigational agents.

7. History of prior severe infusion reaction to a monoclonal antibody. Patients with known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies.

8. Persisting =Grade 2 toxicity (except alopecia) from previous anti-cancer treatment.

9. Patients with > Grade 1 peripheral neuropathy

10. Active or chronic corneal disorder, including but not limited to the following:

• Sjogren's syndrome

• Fuchs corneal dystrophy (requiring treatment)

• History of corneal transplantation

• Active herpetic keratitis

• Active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, and monocular vision.

11. Serious concurrent illness or clinically-relevant active infection, including but not limited to the following:

• Known active hepatitis B or C

• Known Human Immunodeficiency Virus (HIV) infection

• Varicella-zoster virus (shingles)

• Cytomegalovirus infection

• Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment

12. History of cirrhotic liver disease

13. History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment

14. Required used of folate-containing supplements (e.g. for folate deficiency)

15. Pregnancy

16. History of bowel obstruction (including subocclusive disease) related to underlying disease within 6 months of study treatment.

17. Clinically-significant proteinuria defined per protocol

Related Conditions & MeSH terms

• Adenocarcinoma
• Endometrial Adenocarcinoma
• Endometrial Cancer
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Neoplasms
• Endometrial Serous Adenocarcinoma
• Uterine Neoplasms

Intervention

Drug:
• Mirvetuximab Soravtansine
The dose will not be recalculated unless the patient has ±10% weight change.
• Bevacizumab
Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.

Locations

Country	Name	City	State
United States	Stephenson Cancer Center	Oklahoma City	Oklahoma

Sponsors (2)

Lead Sponsor	Collaborator
University of Oklahoma	ImmunoGen, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate of patients who remain progression free		6 months
Primary	Percentage of patients who remain progression free		6 months
Secondary	Incidence of adverse events		up to 3 years
Secondary	Progression free survival		up to 3 years
Secondary	Overall survival		up to 3 years